- The evidence suggests that cognitive assessment tools that are completed by people themselves could be used in the detection and diagnosis of dementia. - There is not enough evidence to recommend ...

Agreement Reached on Primary Endpoint and Phase 3 Trial Design. Oral APX3330 is a Late-Stage Clinical Asset Available for Partnering. FARMINGTON HILLS, Mich., Dec. 19, 2024 (GLOBE ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the imp ...

Extension and the Nevada Association of Counties complete assessment that highlights the lack of public health infrastructure ...

Hyderabad: A five-day intensive course on pre-clinical toxicology and risk assessment was recently held at the University of ...

Devices that are approved through a process that does not require any clinical evidence for FDA authorization should not ...

Every day that we delay updating DSM-5 threat criteria, preventable tragedies unfold. Lives depend on urgent action, and we ...

Residents of Timișoara, in western Romania, can undergo free spirometry tests in a special tram as part of the ...

BrainSee is designed to predict the likelihood of progression from MCI to Alzheimer’s dementia within 5 years, allowing ...

First Patient to Reach 6-Month Follow-up Remains in DORIS Clinical Remission and Free of All Immunosuppressive Therapies SAN DIEGO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: ...

A fully automated algorithm to quantify aortic artery calcification (AAC) on computed tomography (CT) scans performed f ...

A new risk assessment model developed by investigators from the Blood & Marrow Transplant Clinical Trials Network (BMT CTN) ...